Portage Biotech (PRTG) Stock Forecast, Price Target & Predictions
PRTG Stock Forecast
Portage Biotech stock forecast is as follows: an average price target of $19.50 (represents a 369.88% upside from PRTG’s last price of $4.15) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
PRTG Price Target
The average price target for Portage Biotech (PRTG) is $19.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $18.00. This represents a potential 369.88% upside from PRTG's last price of $4.15.
PRTG Analyst Ratings
According to 1 Wall Street analysts, Portage Biotech's rating consensus is 'Buy'. The analyst rating breakdown for PRTG stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Portage Biotech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 01, 2022 | - | H.C. Wainwright | $21.00 | $5.88 | 257.14% | 406.02% |
| Nov 30, 2022 | - | Oppenheimer | $18.00 | $5.96 | 202.01% | 333.73% |
The latest Portage Biotech stock forecast, released on Dec 01, 2022 by H.C. Wainwright company, set a price target of $21.00, which represents a 257.14% increase from the stock price at the time of the forecast ($5.88), and a 406.02% increase from PRTG last price ($4.15).
Portage Biotech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $4.15 | $4.15 | $4.15 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Portage Biotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Portage Biotech's last price of $4.15. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 30, 2022 | Oppenheimer | Outperform | Outperform | Hold |
Portage Biotech's last stock rating was published by Oppenheimer on Nov 30, 2022. The company gave PRTG a "Outperform" rating, the same as its previous rate.
Portage Biotech Financial Forecast
Portage Biotech Revenue Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| Revenue | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| # Analysts | - | - |
| Surprise % | - | - |
Portage Biotech's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRTG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Portage Biotech EBITDA Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| EBITDA | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| Surprise % | - | - |
undefined analysts predict PRTG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Portage Biotech's previous annual EBITDA (undefined) of $NaN.
Portage Biotech Net Income Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| Net Income | - | - |
| Avg Forecast | $1.62M | $1.41M |
| High Forecast | $1.62M | $1.41M |
| Low Forecast | $1.62M | $1.41M |
| Surprise % | - | - |
Portage Biotech's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRTG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Portage Biotech SG&A Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| SG&A | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| Surprise % | - | - |
Portage Biotech's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PRTG last annual SG&A of $NaN (undefined).
Portage Biotech EPS Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| EPS | - | - |
| Avg Forecast | $1.54 | $1.34 |
| High Forecast | $1.54 | $1.34 |
| Low Forecast | $1.54 | $1.34 |
| Surprise % | - | - |
According to undefined Wall Street analysts, Portage Biotech's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRTG previous annual EPS of $NaN (undefined).
Portage Biotech Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FREQ | Korro Bio | $0.30 | $7.00 | 2233.33% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| INZY | Inozyme Pharma | $2.81 | $14.67 | 422.06% | Buy |
| AVTE | Aerovate Therapeutics | $2.67 | $13.00 | 386.89% | Hold |
| PRTG | Portage Biotech | $4.15 | $19.50 | 369.88% | Buy |
| CUE | Cue Biopharma | $1.08 | $4.33 | 300.93% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| FENC | Fennec Pharmaceuticals | $4.28 | $15.75 | 267.99% | Buy |
| ARVN | Arvinas | $21.64 | $71.00 | 228.10% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.39 | $7.00 | 192.89% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| KROS | Keros Therapeutics | $53.62 | $102.60 | 91.35% | Buy |
| HRMY | Harmony Biosciences | $32.48 | $48.86 | 50.43% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.22 | $6.67 | 27.78% | Buy |
| JANX | Janux Therapeutics | $49.01 | $61.20 | 24.87% | Buy |
| BPMC | Blueprint Medicines | $94.60 | $109.71 | 15.97% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |